This project concerns the development of a therapeutic strategy for Central Nuclear Muscular Dystrophy (CNM), a group of very rare and serious myopathies for which no therapy currently exists.

Following the team's initial discovery of the role of Dynamine 2 in one of the 3 CNMs, a Conectus Alsace premature investment was made. All the work carried out by Jocelyn Laporte's team has shown that the decrease, by genetic crossbreeding, in the expression level of Dynamine 2, allows the survival of the mouse models of 2 of the CNMs, and has also allowed the development of an exogenous strategy to decrease the level of Dynamine 2 (by shRNA).